2024-518289-28-00招募中2 期
A Multinational, Long-Term, Open-Label Extension Study of Subjects Who Have Participated in Avalyn Pharma Studies of Inhaled Antifibrotic Agents (AP-LTE-008 [Sail])
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 35
- 试验地点
- 6
- 主要终点
- Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
研究概览
简要总结
To evaluate long-term safety and tolerability outcomes of subjects receiving Avalyn nebulized antifibrotic medications
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Provide written informed consent per the Institutional Review Board/Ethics Committee (IRB/EC)
- •Previously participated in an Avalyn-sponsored inhaled antifibrotic clinical study for subjects with either IPF or PPF and with the approval of the Investigator. IPF is defined as: A specific form of chronic fibrosing interstitial pneumonia limited to the lung and associated with the pathological pattern of usual interstitial pneumonia (American Thoracic Society 2000; Raghu et al, 2018). PPF is defined as: At least 2 of 3 criteria (worsening symptoms, radiological progression, and physiological progression) occurring within the past year with no alternative explanation in a patient with an interstitial lung disease other than IPF (Raghu et al, 2022). Previous participation is defined as: Having completed the final visit of the Treatment Period on the full dose of study drug (either active or placebo).
- •Male subjects and female subjects of childbearing potential (FOCBP) (defined as females who are fertile, following menarche and until becoming post-menopausal unless permanently sterile) agree to use highly effective contraception measures from the time of first dose of study drug (for the male subject) or the signing of the informed consent form (ICF) (for the female subject), during the study, and until 90 days after the last dose of study drug. Subjects agree not to donate eggs or sperm during the same period. Male subjects must use a condom and female partners of male subjects who are of childbearing potential must use a highly effective method of contraception, defined below: a. A highly effective method of contraception is one that results in a low failure rate (i.e., <1% per year) when used consistently and correctly. The acceptable methods of contraception include: i. sexual abstinence, defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the subject. ii. a vasectomized partner iii. bilateral tubal occlusion iv. any effective intrauterine device/hormone-releasing system, and progesterone-only (oral, injectable, or implantable) or combined (estrogen- and progesterone-containing; oral, intravaginal, or transdermal) hormonal contraception associated with inhibition of ovulation. Note: Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea method are not acceptable methods of contraception. b. The efficacy of oral hormonal contraceptives may be compromised by vomiting and/or diarrhea or other conditions where the drug absorption may be reduced. Advise women taking oral hormonal contraceptives experiencing these conditions to use alternative highly effective contraception. Note: Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and/or bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. In the absence of 12 months of amenorrhea, a single folliclestimulating hormone measurement is insufficient to document menopause.
- •Willingness to comply with all study visits and requirements.
- •Male or female at least 18 years of age at Screening/Baseline (Day 1).
排除标准
- •Have not previously participated in an Avalyn-sponsored inhaled antifibrotic lead-in study or if the subject was permanently discontinued from the lead-in study for any reason. Subjects who discontinued study drug but continued to attend study visits are ineligible.
- •Subjects who experienced an exacerbation of asthma or of chronic obstructive pulmonary disease (COPD) requiring oral or systemic corticosteroids within 3 months of Day 1 (Screening/Baseline Visit).
- •Subjects who experienced an acute exacerbation of IPF or of PPF (as defined in Section 12.2.3) within 3 months of Day 1 (Screening/Baseline Visit).
- •Any conditions or abnormalities (including electrocardiogram [ECG] or laboratory abnormalities) which, in the opinion of the Investigator may compromise the safety of the subject or interfere with the subject participating in or completing the study.
- •History of non-adherence to medical regimens, unreliability, medical condition, mental instability or cognitive impairment that, in the opinion of the Investigator, could compromise the validity of informed consent, compromise the safety of the subject, or lead to non-adherence with the study protocol or inability to conduct the study procedures.
- •Participation in a concurrent clinical study or in a clinical study in which any other investigational drug product aside from the Avalyn nebulized antifibrotic medication from their lead-in study was administered within the previous 30 days, or 5 half-lives of the previously administered investigational product, whichever is longer. Subjects may be enrolled in registries.
- •History of hypersensitivity and/or allergic reaction to pirfenidone or the excipients to be used in this study.
- •Is pregnant, nursing, or who plans to become pregnant while in the study.
结局指标
主要结局
Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
Incidence of adverse events of special interest (AESIs)
Incidence of adverse events of special interest (AESIs)
Incidence of treatment-emergent all-cause deaths
Incidence of treatment-emergent all-cause deaths
Incidence of treatment-emergent respiratory deaths
Incidence of treatment-emergent respiratory deaths
Incidence of exacerbation of pulmonary fibrosis
Incidence of exacerbation of pulmonary fibrosis
Changes from baseline in clinical laboratory tests and vital signs
Changes from baseline in clinical laboratory tests and vital signs
次要结局
- Change from baseline in forced vital capacity (FVC) (mL) at intervals of 6 months
- Annual rate of decline in FVC (mL)
研究者
Dr Felix Woodhead, MA MB BChir FRCP PhD Senior Medical Director, Avalyn Pharma Inc.
Scientific
Avalyn Pharma Inc.
研究点 (6)
Loading locations...
相似试验
招募中
2 期
An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal HyperplasiaClassic Congenital Adrenal HyperplasiaCongenital Adrenal HyperplasiaNCT06712823Crinetics Pharmaceuticals Inc.200
已完成
3 期
Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular ("Wet") Age-related Macular Degeneration (AMD)Neovascular Age-related Macular DegenerationNCT00964795Regeneron Pharmaceuticals323
已完成
1 期
A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP)Acute Intermittent PorphyriaNCT02949830Alnylam Pharmaceuticals16
已完成
2 期
A Study of Cariprazine in Patients With Chronic Stable SchizophreniaSchizophreniaNCT00839852Forest Laboratories97
终止
2 期
Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer PatientsProstate CancerNCT00215657Ferring Pharmaceuticals131